INTRODUCTION: Pressure ulcers (PU) are one of the main challenges for nursing in our country. Wound bed preparation and the TIME algorithm provide essential tools for adequately treating these lesions. However, these wounds tend to become chronic due to the bacterial load in their bed. It is now known that bacteria can form complex and diverse structures, named as biofilm, which are difficult to diagnose and much more resistant to antimicrobial action.
Controlling these biofilms is crucial to create the optimal conditions for wound healing. Currently, it is believed that biofilms are present in 60-100% of chronic wounds. Therefore, more studies are needed to evaluate the efficacy of different antimicrobial agents on these structures.
OBJECTIVE: To determine the efficacy of a gel containing polyhexanide and biguanide, alone or in combination with alginate with or without silver, in preventing biofilm in PU, in terms of healing at 4 weeks.
METHODOLOGY: Multicenter clinical trial with a 2x2 factorial design, conducted with patients from Alcoy with category II and III PUs that meet the inclusion and exclusion criteria. A sample of 140 participants is estimated, distributed into four groups of 35 patients. The interventions that will be carried out will be: application of Prontosan gel® and Aquacel Ag+®; Aquacel Ag+®; control group; Prontosan gel®. Data on wound evolution will be collected using RESVECH 2.0. Descriptive statistical analysis and hypothesis testing will be performed.

Start Date30 Jan 2026

Sponsor / Collaborator-

IRCT20190210042676N49

/ RecruitingPhase 2

Evaluation of effectiveness and safety of antibacterial dressing containing polyhexamethylene biguanide in treatment of chronic wounds

Start Date21 Dec 2025

Sponsor / Collaborator-

NCT07195864

/ CompletedNot Applicable

Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/mL Polihexanide as Part of the "Medicines in Special Situations" (Medicamentos en Situaciones Especiales) Program in Spain.

The study will be a multicentric, retrospective, non-interventional medical chart review of patients with AK who initiated a treatment with 0.8 mg/ml polihexanide as part of the Spanish Medicines in Special Situations program, whether they fully completed the treatment or not.
Baseline date is defined as the date of 0.8 mg/ml polihexanide initiation. The Study Period for each patient will be considered the period from the baseline to the conclusion of the treatment.

Start Date30 Oct 2025

Sponsor / Collaborator

SIFI SpA

100 Clinical Results associated with Polihexanide

100 Translational Medicine associated with Polihexanide

100 Patents (Medical) associated with Polihexanide

821

Literatures (Medical) associated with Polihexanide

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Effects of extended-release topical polyhexanide in a Staphylococcus aureus–induced murine dermatitis model characterized by IL-36 expression

Article

Author: Bresnick, Stephen ; Burnam, Bradley

OBJECTIVES:

Atopic dermatitis is a chronic inflammatory skin disorder characterized by epidermal barrier dysfunction, microbial dysbiosis, and dysregulated immune signaling. Staphylococcus aureus colonization is associated with disease severity and contributes to inflammatory amplification, with IL-36 serving as a marker of epithelial stress. Polyhexanide is a cationic polymer delivered in topical formulations. GX03 is a novel extended-release topical formulation designed to provide sustained delivery of liquid polyhexanide at the skin surface. This study evaluated whether GX03 reduces disease severity in a murine model of S. aureus-induced cutaneous inflammation characterized by IL-36 expression.

METHODS:

Skin inflammation was induced using a standardized S. aureus exposure protocol, with confirmation of IL-36 protein expression. Animals were treated topically with GX03 or left untreated. Disease severity was assessed with blinded investigator global assessment scoring using the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD).

RESULTS:

Epicutaneous S. aureus exposure produced reproducible inflammatory disease with consistent IL-36 expression. Treatment with GX03 resulted in a significant reduction in disease severity, with mean global assessment scores decreasing from 3.00 in untreated controls to 1.44 in treated animals (52% reduction; p = 0.0003).

CONCLUSIONS:

These findings suggest that extended-release topical polyhexanide (GX03) reduces disease severity in a murine dermatitis model characterized by IL-36 expression.

01 Dec 2026·PARASITOLOGY RESEARCH

Multidrug-resistant Acanthamoeba keratitis caused by the T4 Genotype: A case report

Article

Author: Kazemirad, Elham ; Atighehchian, Mehrnaz ; Kasiri, Maryam ; Zarei-Ghanavati, Mehran ; Latifi, Alireza

This report describes the case of a 28-year-old woman, who presented with a two-week history of severe ocular pain and photophobia in her right eye. She was a soft contact lens wearer with no history of ocular trauma or systemic illness. Ophthalmic examination revealed conjunctival hyperemia, epithelial irregularities, and a developing ring-shaped stromal infiltrate. In vivo confocal microscopy demonstrated double-walled hyperreflective cysts, and culture followed by PCR and sequencing confirmed the presence of Acanthamoeba T4 genotype. Despite intensive treatment with topical polyhexamethylene biguanide, chlorhexidine, propamidine, and voriconazole, as well as oral miltefosine, the infection progressed, leading to stromal necrosis. The patient underwent two therapeutic penetrating keratoplasties; however, the disease continued to advance, eventually resulting in phthisis bulbi and permanent vision loss. This case highlights the potential for aggressive, clinically refractory Acanthamoeba keratitis caused by the T4 genotype, emphasizing the importance of early diagnosis, vigilant monitoring, and timely surgical intervention in resistant cases.

01 Sep 2026·JOURNAL OF DENTISTRY

Antiseptic mouthwashes as a potential strategy for controlling oral dysbiosis: Antimicrobial effect against opportunistic pathogens

Article

Author: Cielecka-Piontek, Judyta ; Paczkowska-Walendowska, Magdalena ; Karpiński, Tomasz M ; Korbecka-Paczkowska, Marzena

OBJECTIVES:

Oral dysbiosis is increasingly recognized as a clinically relevant condition associated with oral diseases, systemic complications, and the emergence of antimicrobial-resistant microorganisms. Antiseptic-containing mouthwashes are widely used as adjunctive, non-antibiotic tools in oral hygiene; however, comparative data on their activity against dysbiosis-associated microorganisms and their clinical efficiency at formulation-relevant concentrations remain limited.

METHODS:

In this study, the antimicrobial activity of commercially available mouthwashes containing octenidine dihydrochloride (OCT), chlorhexidine digluconate (CHX), polyhexamethylene biguanide (PHMB), and cetylpyridinium chloride (CPC) was evaluated against Gram-positive and Gram-negative bacteria and Candida spp. associated with oral dysbiosis. Minimum inhibitory concentrations (MICs) were determined by broth microdilution and expressed both as product dilutions and active compound concentrations. Clinical relevance was assessed using the Clinical Efficiency of MIC (CEMIC) index.

RESULTS:

OCT-containing mouthwashes demonstrated the lowest MIC and CEMIC values and the most consistent antimicrobial activity against all tested microorganisms. CHX-based formulations showed high activity against Gram-positive bacteria and Candida spp. but were markedly less effective against Gram-negative pathogens. PHMB exhibited lower antimicrobial potency; however, its CEMIC values indicated clinical efficiency at formulation-relevant concentrations.

CONCLUSIONS:

The results demonstrate in vitro antimicrobial activity of antiseptic mouthwashes against microorganisms associated with oral dysbiosis and suggest that they may have potential as non-antibiotic adjuncts, although this requires clinical validation.

CLINICAL SIGNIFICANCE:

This study demonstrates that antiseptic mouthwashes, particularly those containing octenidine, chlorhexidine and polyhexanide, effectively control oral dysbiosis at commercial concentrations. By using the CEMIC index, our findings provide evidence-based guidance for non-antibiotic oral care, reduce antimicrobial resistance risk, and support improved oral health.

News (Medical) associated with Polihexanide

20 Aug 2026

·www.biospace.com

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7% Findings support Turn’s approach of acting earlier in the inflammatory process, before inflammation becomes fully established WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with inflammatory skin disease. The study, published in Life , showed that pretreatment with GX-03 reduced IL-36α and IL-36γ release by approximately 50%. IL-36 is an important early signal in the inflammatory cascade and helps amplify inflammation in the skin. GX-03 also reduced IL-31 by nearly 68%. IL-31 is closely associated with itch in inflammatory skin diseases such as atopic dermatitis. In addition, IL-4, another important inflammatory cytokine involved in the immune response, was reduced by 16.7%. Importantly, IL-13 was essentially unchanged, suggesting that GX-03 did not suppress every inflammatory signal measured, but instead produced a selective pattern of cytokine reduction. These biological changes were accompanied by a 66% reduction in clinical dermatitis severity in GX-03-pretreated animals compared with untreated controls. “This publication provides important new biological evidence about GX-03,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. “In-vivo, GX-03 strongly reduced IL-36, a key early driver of the inflammatory cascade, as well as IL-31, a major driver of itch. It also reduced IL-4, an important inflammatory signal. What is particularly interesting is when this occurred. Rather than targeting inflammation only after it is already established, GX-03 was present before the challenge and substantially reduced the inflammatory response that followed skin challenge. We believe this supports a fundamentally different approach: modifying the local skin environment upstream, before the inflammatory cascade takes hold.” The timing of the intervention is an important part of the study. Many current therapies for atopic dermatitis are designed to block inflammatory pathways after disease and inflammation are already established. In this study, researchers applied GX-03 before exposing the skin to a standardized bacterial challenge known to trigger atopic dermatitis-like inflammation. They then measured the inflammatory response that developed afterward. Animals pretreated with GX-03 developed substantially less severe dermatitis and showed significant reductions in IL-36α, IL-36γ, IL-31 and IL-4. The study therefore provides a different experimental perspective on inflammatory skin disease by examining whether modifying the skin environment can change the intensity and pattern of the inflammatory response. The study evaluated 40 mice that received either no pretreatment or four days of topical GX-03 before standardized Staphylococcus aureus exposure. Following predefined exclusions, 18 animals in each group were included in the final analysis. GX-03 pretreatment reduced mean clinical disease severity from a vIGA-AD score of 2.44 in untreated animals to 0.83, representing a 66.0% reduction. IL-36α expression decreased by 49.9%, IL-36γ by 50.9%, IL-31 by 67.7%, and IL-4 by 16.7%. IL-13 did not differ significantly between the groups. No local irritation, dryness, redness, barrier disruption or other adverse skin findings were observed during the GX-03 pretreatment period. The publication, titled “Effects of Extended-Release Polyhexanide on Inflammatory Cytokine Expression and Disease Severity Following Staphylococcus aureus Exposure in a Murine Dermatitis Model,” was co-authored by Bradley Burnam, Chief Executive Officer of Turn Therapeutics, and Stephen D. Bresnick, M.D., an independent researcher. The study was conducted at Altogen Labs under an IACUC-approved protocol and builds upon Turn Therapeutics’ previously published research in the Journal of Dermatological Treatment . About GX-03 GX-03 is Turn Therapeutics’ proprietary, non-systemic topical investigational therapy currently in clinical development for atopic dermatitis. GX-03 is designed to act locally in the skin, where Turn is investigating whether modifying the local skin environment can reduce important inflammatory signals associated with disease while avoiding broad systemic immune suppression. The newly published findings provide in-vivo evidence that GX-03 is associated with selective reductions in IL-36, IL-31 and IL-4 following a standardized skin challenge. GX-03 is currently being evaluated in a randomized, double-blind, vehicle-controlled clinical trial in atopic dermatitis. About Turn Therapeutics Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. GX-03 is Turn Therapeutics’ lead investigational topical candidate and is being developed as a targeted, non-systemic treatment for atopic dermatitis. Citation Burnam B, Bresnick S. Effects of Extended-Release Polyhexanide on Inflammatory Cytokine Expression and Disease Severity Following Staphylococcus aureus Exposure in a Murine Dermatitis Model. Life . 2026. DOI: 10.3390/life16081369 Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding clinical development plans, optimization of enrollment criteria and endpoints, interpretation of interim clinical observations, expected trial timing, regulatory interactions, and the therapeutic potential of GX-03. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success of development programs, the availability of additional financing, and the Company’s ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise. Contacts Turn Therapeutics Investor & Media Contact Sasha Damouni The Damouni Group Sasha@turntherapeutics.com

Clinical Result

01 Jun 2026

·www.businesswire.com

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled Phase 2 clinical trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis. “What became increasingly apparent during the interim review was the speed with which responses emerged." The interim review was conducted under the study’s established independent data monitoring committee (“IDMC”) framework. Upon the advice of the Company’s independent statisticians and clinical and regulatory advisors, including former FDA Commissioner Dr. Stephen Hahn, Turn Therapeutics elected to utilize the completed cohort as an integrated Stage 1 analysis to comprehensively evaluate responder dynamics, endpoint sensitivity, inflammatory burden behavior, and opportunities to optimize the second stage of the trial while enrollment continued. The Company believed that the complexity of atopic dermatitis and the evaluation of efficacy across multiple clinical endpoints and timepoints warranted a broader assessment than conditional probability analysis of a single endpoint to inform trial optimization, future regulatory planning, and better characterize where GX-03 treatment effects appear most visible. Within the completed interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in overall eczema severity within 4 weeks (EASI-50) compared to 65.2% for vehicle-treated subjects. Additional separation was observed across deeper responder thresholds designed to measure near-clearance of disease, including Week 4 EASI-90 responses (90% reduction) of 44.4% for GX-03 versus 30.4% for vehicle, which further increased to 51.9% versus 34.8%, respectively, by Week 8. These findings suggest that a substantial proportion of GX-03-treated subjects experienced rapid and progressively deeper reductions in eczema severity over the course of treatment. There were no observed or reported treatment-related serious adverse events during the interim analysis period, no treatment-related tolerability concerns reported by subjects, and no treatment-related discontinuations, with GX-03 continuing to demonstrate a favorable safety and tolerability profile. “What became increasingly apparent during the interim review was the speed with which responses emerged,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. “The review identified opportunities to refine enrollment criteria and endpoint selection while providing valuable insight into where GX-03 activity appears most visible. The consistency of response across earlier efficacy measures suggests clinically meaningful improvement may emerge sooner than originally anticipated, which could have important implications for both future regulatory strategy and patient outcomes.” Skin and inflammatory disease expert Dr. Stephen Bresnick, who recently coauthored a peer-reviewed publication on GX-03 and its role in modulating inflammatory signaling within the skin microenvironment, commented: “In inflammatory skin disease, earlier control can have a meaningful impact on both disease burden and patient quality of life. Seeing rapid responder activity alongside a favorable safety and tolerability profile is encouraging and supports the potential for GX-03 to become an important first-line treatment option if these findings continue to be observed as development progresses.” The Company is now strategically utilizing the interim findings to optimize the remainder of the trial, including refinement of enrollment criteria to better control for baseline EASI and body surface area involvement in a manner more consistent with comparable atopic dermatitis studies, as well as increased focus on earlier inflammatory burden endpoints following observation of higher-than-anticipated vehicle response within subsets of the study population. Enrollment has continued throughout the interim analysis process and is nearing completion of the originally planned target population. In parallel, the Company is preparing to initiate FDA interactions, including a requested meeting to discuss the evolving regulatory strategy for GX-03 and potential pathways that may support more efficient advancement of the program toward market following successful completion of the trial. Turn Therapeutics plans to present detailed findings during the Jefferies Global Healthcare conference in New York on June 4, 2026. A live webcast of the presentation may be accessed on the Investors section of the Turn Therapeutics website at https://ir.turntherapeutics.com/news-events/events. About GX-03 GX-03 is an investigational extended-release topical formulation designed to provide sustained localized exposure to polyhexanide at the skin surface. GX-03 is being developed as a targeted, localized therapy for inflammatory skin diseases. About Turn Therapeutics Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding clinical development plans, optimization of enrollment criteria and endpoints, interpretation of interim clinical observations, expected trial timing, regulatory interactions, and the therapeutic potential of GX-03. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success of development programs, the availability of additional financing, and the Company’s ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise.

Phase 2Clinical Result

27 May 2026

·www.biospace.com

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

Study demonstrates statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression First in a planned series of peer-reviewed publications exploring the scientific rationale and non-systemic mechanism underlying GX-03, currently in Phase 2 evaluation for moderate-to-severe atopic dermatitis WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the effects of its lead program, GX-03, in an IL-36–associated inflammatory environment. The publication, titled “Effects of extended-release topical polyhexanide in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression,” was co-authored by Bradley Burnam, Chief Executive Officer of Turn Therapeutics, and Stephen Bresnick, M.D., a practicing physician, researcher, and advisor to the Company. “This publication demonstrates a shift in how inflammatory skin disease should be studied. Rather than inferring biology from systemic markers, we evaluated GX-03 directly within an IL-36–associated inflammatory environment and observed a clear clinical effect following seven days of twice-daily treatment,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. “This is about building a more precise understanding of what is driving inflammation in the skin, at the site of disease. We’re helping define a framework for evaluating targeted, localized therapies in dermatology.” Study Highlights GX-03 was evaluated in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression IL-36 protein expression was confirmed following Staphylococcus aureus exposure, establishing the inflammatory environment in which GX-03 was evaluated Mice treated twice daily with GX-03 for seven days achieved a mean investigator global assessment score of 1.44 versus 3.00 in untreated controls (p = 0.0003) No treatment-related adverse effects were observed IL-36 is a cytokine associated with epithelial stress and is minimally expressed in healthy skin but becomes upregulated in response to microbial dysbiosis and barrier disruption. The study confirmed reproducible IL-36 expression following Staphylococcus aureus exposure, establishing a relevant inflammatory context in which GX-03 demonstrated clinical activity. This publication supports the Company’s broader approach of targeting disease at the site of origin. The article represents the first in a planned series of scientific publications evaluating GX-03’s clinical and biological activity, with a subsequent manuscript already in review characterizing the mechanistic implications of treatment. About GX-03 GX-03 is a first-in-class, non-systemic, topical cytokine-modulating therapy in development for moderate-to-severe atopic dermatitis (eczema). By stabilizing the cutaneous microenvironment and modulating epithelial danger sensing, GX-03 is designed to address IL-36, IL-4, IL-13, and IL-31 signaling through upstream prevention rather than downstream, systemic suppression. GX-03 is currently being evaluated in a Phase 2 randomized controlled trial. About Turn Therapeutics Turn Therapeutics is a biotechnology company focused on developing innovative, precision therapies that target the underlying causes of inflammatory diseases with high unmet needs. Its lead investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor currently in development for the treatment of moderate-to-severe atopic dermatitis. This therapy is designed to modulate key inflammatory pathways involved in eczema and other inflammatory dermatological conditions, specifically targeting IL-36 and IL-31, two cytokines that play distinct but interconnected roles in driving chronic skin inflammation and the itch-scratch cycle. GX-03 addresses IL-36 upstream, where epithelial stress and barrier disruption initiate the inflammatory cascade, and IL-31 downstream, where itch signaling perpetuates disease. Citation Burnam B, Bresnick S. Effects of Extended-Release Topical Polyhexanide in a Staphylococcus aureus –Induced Murine Dermatitis Model Characterized by IL-36 Expression. Journal of Dermatological Treatment . 2026. Article ID: IJDT 2667686. DOI: Forward-Looking Statement Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success of development programs, and the Company’s ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s filings with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026. All such forward-looking statements speak only as of the date they are made, and Turn undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise. Contacts Investor Relations / Media Contact Sasha Damouni Damouni Group LLC Sasha@damounigroup.com

Phase 2Clinical Result

100 Deals associated with Polihexanide

External Link

KEGG	Wiki	ATC	Drug Bank
D08399	Polihexanide	D08AC05	DB12277

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acanthamoeba Keratitis	European Union	SIFI SpA	22 Aug 2024
Acanthamoeba Keratitis	Iceland	SIFI SpA	22 Aug 2024
Acanthamoeba Keratitis	Liechtenstein	SIFI SpA	22 Aug 2024
Acanthamoeba Keratitis	Norway	SIFI SpA	22 Aug 2024
Disinfectants	-	B. Braun Medical, Inc.	-
Wounds and Injuries	-	B. Braun Medical, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03274895 (Pubmed) Manual	Phase 3	Acanthamoeba Keratitis	127	PHMB 0.02%+ propamidine 0.1%	zcutzncmvk(porrtbzoxn) = iylhgjaoxo rpistxtpdq (lvgamiboph ) View more	Positive	01 Mar 2024
				PHMB 0.08%+ placebo	zcutzncmvk(porrtbzoxn) = xydttjwgjg rpistxtpdq (lvgamiboph ) View more
NCT03274895 (The Orphan Drug for Acanthamoeba Keratitis (ODAK) Trial, CTgov)	Phase 3	Acanthamoeba Keratitis	135	placebo+PHMB 0.08% (PHMB 0.08% Plus Placebo)	dwtiyrxrda = nehmwdnevp lihnbodwci (yqlbtezjbr, ykezyzuart - xlwdvvzahv) View more	-	02 Aug 2023
				Propamidine 0.1%+PHMB 0.02% (PHMB 0.02% Plus Propamidine 0.1%)	dwtiyrxrda = qloedepeya lihnbodwci (yqlbtezjbr, ftdmonuuuf - ewucbcdday) View more
NCT03274895 (PRNewswire) Manual	Phase 3	Acanthamoeba Keratitis	135	Placebo+Polihexanide	qwntqzqtjk(vzlcxeyzsd) = ngrcpermjq ipmticpdsp (byacksschm ) View more	Non-inferior	13 Oct 2022
				polihexanide+Polihexanide	qwntqzqtjk(vzlcxeyzsd) = ioupwmjbpj ipmticpdsp (byacksschm ) View more
NCT04055233 (RECIPE, Pubmed \| Ann Surg)	Phase 3	Surgical Wound Infection	456	Antiseptica (0.9% saline)	tbvdemlzey(htytyppgtj) = puffdcneam rdbquvfxkw (ulyepmtxpg )	Positive	01 Jul 2020
NCT02506257 (CTgov)	Phase 1	Acanthamoeba Keratitis	90	0.04% PHMB (0.04% PHMB)	iowxdguwsq = pjhszckyag cgqbhgppja (bxiyskbyhg, kjzgomaulo - mjtjrmunxj) View more	-	23 Nov 2016
				0.06% PHMB (0.06% PHMB)	iowxdguwsq = ayvpeocgqc cgqbhgppja (bxiyskbyhg, gonynttuux - owsqfecgzd) View more
ODAK (ARVO2014)	Not Applicable	Acanthamoeba Keratitis	100	Polyhexamethylene biguanide (PHMB)	fmdztrmumb(wzjokwethg) = idensymdho cdxtwrhpyo (bprezvrpvb )	-	01 Apr 2014
				Combination therapy (PHMB and propamidine)	fmdztrmumb(wzjokwethg) = qwrjqzjhxe cdxtwrhpyo (bprezvrpvb )
NCT01153620 (Lavasept 2, CTgov)	Phase 4	Wounds and Injuries	61	Lavasept 0.04% (Lavasept 0.04%)	pcwzctqyhz(joyqstpboo) = zfisedjgst qxwoacdktn (ugnluejelm, 1.00) View more	-	29 Nov 2011
				Ringer's Solution (Ringer's Solution)	pcwzctqyhz(joyqstpboo) = hnefnzojqw qxwoacdktn (ugnluejelm, 0.85) View more
AAO2004	Not Applicable	-	43	Polyhexamethylene Biguanide (PHMB)	mxntwixdhl(esvvdrqklg) = yjfkvsbqvn iupimxputl (jkzxoaapqv ) View more	Negative	25 Oct 2004
				Chlorhexidine (CH)	mxntwixdhl(esvvdrqklg) = tsgbvjbntf iupimxputl (jkzxoaapqv ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis